Low nadir CD4 cell count predicts sustained hypertension in HIV-infected individuals

J Clin Hypertens (Greenwich). 2013 Feb;15(2):101-6. doi: 10.1111/jch.12029. Epub 2012 Oct 26.

Abstract

Hypertension is associated with cardiovascular disease in the human immunodeficiency virus (HIV)-infected population. The authors aimed to test the hypothesis whether advanced immunosuppression with low nadir CD4 lymphocyte cell count is a predictor of sustained hypertension in HIV-infected individuals. In a longitudinal study of an HIV cohort of 434 patients (43±11 years, 72% men, 71% Caucasians), standardized blood pressure was measured in duplicate during 3 clinical visits both at baseline and after 3.4±0.8 years. The lowest CD4 cell count in the individual history was recorded as nadir CD4. Both nadir CD4 cell count<50 cells/μL and duration of antiretroviral therapy (ART) were associated with sustained hypertension, and the highest proportion of hypertensive patients was observed in those who had both nadir CD4 cell count<50 cells/μL and prolonged ART duration. Nadir CD4 cell-count<50 cells/μL was an independent predictor of hypertension (adjusted odds ratio [OR], 2.48; 95% confidence interval [CI], 1.27-4.83), as was ART duration (adjusted OR, 1.13; 95% CI, 1.03-1.24). The predictive power of ART duration was more pronounced in patients with nadir CD4 cell count<50 cells/μL. Delaying ART initiation until a state of advanced immunosuppression might add to and even fuel the cardiovascular risk associated with ART.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Retroviral Agents / therapeutic use
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / pathology*
  • Cohort Studies
  • Comorbidity
  • Female
  • Follow-Up Studies
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology*
  • Humans
  • Hypertension / diagnosis*
  • Hypertension / epidemiology
  • Hypertension / immunology*
  • Immunosuppression Therapy
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Prospective Studies

Substances

  • Anti-Retroviral Agents